152 related articles for article (PubMed ID: 37725627)
21. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
22. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
23. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.
Kuang T; Zhang L; Chai D; Chen C; Wang W
Aging (Albany NY); 2023 Jun; 15(12):5751-5774. PubMed ID: 37354485
[TBL] [Abstract][Full Text] [Related]
24. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
25. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
26. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma.
Xin H; Lai Q; Zhou Y; He J; Song Y; Liao M; Sun J; Li M; Zhang M; Liang W; Bai Y; Zhang Y; Zhou Y
Front Immunol; 2023; 14():1134521. PubMed ID: 37520528
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of a m7G-related lncRNA signature for predicting the prognosis and therapy response in hepatocellular carcinoma.
Peng YL; Dong YF; Guo LL; Li MY; Liao H; Li RS
PLoS One; 2023; 18(8):e0289552. PubMed ID: 37535570
[TBL] [Abstract][Full Text] [Related]
31. Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.
Ding D; Wang L; Zhang Y; Shi K; Shen Y
Transl Oncol; 2023 Dec; 38():101784. PubMed ID: 37722290
[TBL] [Abstract][Full Text] [Related]
32. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma.
Ma J; Kuang L; Zhao R
Aging (Albany NY); 2022 Dec; 14(23):9699-9714. PubMed ID: 36516498
[TBL] [Abstract][Full Text] [Related]
33. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden.
Tang B; Zhu J; Zhao Z; Lu C; Liu S; Fang S; Zheng L; Zhang N; Chen M; Xu M; Yu R; Ji J
J Adv Res; 2021 Nov; 33():153-165. PubMed ID: 34603786
[TBL] [Abstract][Full Text] [Related]
35. Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma.
Li N; Ren SH; Qin YF; Shao B; Qin H; Wang Z; Wang HD; Li GM; Zhu YL; Sun CL; Zhang JY; Shi GG; An XW; Wang H
Biomed Res Int; 2022; 2022():2680110. PubMed ID: 35782053
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
38. Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment.
Zhu L; Zhang XP; Xu S; Hu MG; Zhao ZM; Zhao GD; Xiao ZH; Liu R
Front Immunol; 2022; 13():1111246. PubMed ID: 36700197
[TBL] [Abstract][Full Text] [Related]
39. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
40. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.
Huo J; Wu L; Zang Y; Dong H; Liu X; He F; Zhang X
BMC Cancer; 2021 Jan; 21(1):31. PubMed ID: 33413205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
